Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Silo Pharma, Inc.

< Previous 1 2 Next >
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma to Present at Psychedelic Drug Development Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers SILO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.